The challenging treatment of Behcet’s disease

Bibliography

• Rasmussen N. The 2012 revised international Chapel Hill consensus nomenclature of the vasculitides. Ann Rheum Dis 2012;71:16
   Web of Science ®Google Scholar
• Gul A. Genetics of Behcet’s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol 2014;26:56-63
   PubMed Web of Science ®Google Scholar
• McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297
   PubMed Web of Science ®Google Scholar
• Consolandi C, Turroni S, Emmi G, et al. Behcet’s syndrome patients exhibit specific signature. Autoimmun Rev 2015;14:269-76
   PubMed Web of Science ®Google Scholar
• Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med 1999;341:1284-91
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B. Behcet’s disease. Orphanet J Rare Dis 2012;7:20
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990;335:1078-80
   PubMed Web of Science ®Google Scholar
• International Team for the Revision of the International Criteria for Behcet`s Disease (ITR-ICBD). The international criteria for Behcet`s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venerol 2014;28:338-47
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol 2004;16:38-42
   PubMedGoogle Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008;67:1656-62
   PubMed Web of Science ®Google Scholar
• Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behcet’s syndrome. Rheumatology (Oxford) 2006;45:348-52
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593-7
   Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 1990;322:281-5
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behcet’s disease. Arthritis Care Res (Hoboken) 2010;62:1733-8
   PubMed Web of Science ®Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc 1988;20:136-43
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 1989;1:1093-6
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol 1992;76:241-3
   PubMed Web of Science ®Google Scholar
• Martin M, Gil H, Hafsaoui C, et al. [Role of cyclosporine in the occurrence of neuro-Behcet’s disease?]. Rev Med Interne 2010;31:e7-8
   PubMedGoogle Scholar
• Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behcet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 2008;26:S84-90
   PubMed Web of Science ®Google Scholar
• Riera-Mestre A, Martinez-Yelamos S, Martinez-Yelamos A, et al. [Neuro-Behcet and neurotoxicity due to cyclosporine]. Rev Clin Esp 2008;208:205-6
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases. Clin Rheumatol 2006;25:482-6
   PubMed Web of Science ®Google Scholar
• Kato Y, Numaga J, Kato S, et al. Central nervous system symptoms in a population of Behcet’s disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001;29:335-6
   PubMed Web of Science ®Google Scholar
• Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9
   PubMed Web of Science ®Google Scholar
• Mimesh S, Obeid T, Al-Shami A, et al. Cyclosporine therapy. Does it provoke neurological complications in Behcet`s disease. Neurosciences (Riyadh) 2003;8:123-5
   PubMedGoogle Scholar
• Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41:61-70
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behcet’s disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012;130:592-8
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010;94:284-8
   PubMed Web of Science ®Google Scholar
• Adan A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. Int Ophthalmol 2010;30:577-81
   PubMedGoogle Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet’s disease: experience in 19 patients. Rheumatology (Oxford) 2012;51(10):1825-31
   PubMed Web of Science ®Google Scholar
• Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behcet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol 2014;32:S58-62
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014;53:2223-31
   PubMed Web of Science ®Google Scholar
• Mesquida M, Victoria Hernandez M, Llorenc V, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 2013;21:160-2
   PubMed Web of Science ®Google Scholar
• Touzot M, Cacoub P, Bodaghi B, et al. IFN-alpha induces IL-10 production and tilt the balance between Th1 and Th17 in Behcet disease. Autoimmun Rev 2015;14:370-5
   PubMed Web of Science ®Google Scholar
• Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease. Rheumatology (Oxford) 2011;50:293-8
   PubMed Web of Science ®Google Scholar
• Amberger M, Groll S, Gunaydin I, et al. Intracellular cytokine patterns in Behcet’s disease in comparison to ankylosing spondylitis--influence of treatment with interferon-alpha2a. Clin Exp Rheumatol 2007;25:S52-7
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71
   PubMed Web of Science ®Google Scholar
• Demiroglu H, Ozcebe OI, Barista I, et al. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet’s disease: a randomised trial. Lancet 2000;355:605-9
   PubMed Web of Science ®Google Scholar
• Demiroglu H. Final verdict of the Turkish Supreme Courts. Br J Ophthalmol 2008;92:423
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. Isr Med Assoc J 2002;4:928-30
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet`s disease. Arthr Rheum 2010;62:2796-805
   PubMed Web of Science ®Google Scholar
• Lightman S, Taylor SR, Bunce C, et al. Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis 2015;74(6):1138-44
   PubMed Web of Science ®Google Scholar
• Ait Ben Haddou EH, Imounan F, Regragui W, et al. Neurological manifestations of Behcet’s disease: Evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012;168:344-9
   PubMed Web of Science ®Google Scholar
• Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet’s disease. Arthritis Rheum 2012;64:2753-60
   PubMed Web of Science ®Google Scholar
• Silvestri E, Emmi G, Prisco D. Vascular Behcet’s disease: new insights in the management of thrombosis. Expert Rev Cardiovasc Ther 2013;11:1583-5
   PubMedGoogle Scholar
• Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012;46:e38-45
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50
   PubMed Web of Science ®Google Scholar
• Jung YS, Cheon JH, Park SJ, et al. Clinical course of intestinal Behcet’s disease during the first five years. Dig Dis Sci 2013;58:496-503
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009;19(5):542-9
   PubMed Web of Science ®Google Scholar
• Kose O, Dinc A, Simsek I. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behcet’s disease. Dermatology 2009;218:140-5
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 2001;44:2686-92
   PubMed Web of Science ®Google Scholar
• Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology 1996;192:125-8
   PubMed Web of Science ®Google Scholar
• Calguneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet’s disease. A randomized clinical trial. Arthritis Rheum 1996;39:2062-5
   PubMed Web of Science ®Google Scholar
• Al-Waiz MM, Sharquie KE, MH AQ, Hayani RK. Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J 2005;11:3
   PubMedGoogle Scholar
• Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet’s disease. J Neurol Sci 1998;159:181-5
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002;29:267-79
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999;135:529-32
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK. Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study. J Dermatol 2006;33:541-6
   PubMed Web of Science ®Google Scholar
• Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet’s disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003;4:19-28
   PubMedGoogle Scholar
• Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet’s disease. Inflamm Bowel Dis 2010;16:188-9
   PubMed Web of Science ®Google Scholar
• Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol Inflamm 2001;9:219-29
   PubMed Web of Science ®Google Scholar
• O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med 1984;76:75-84
   PubMed Web of Science ®Google Scholar
• Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet’s disease. Dermatology 2001;203:322-4
   PubMed Web of Science ®Google Scholar
• Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet’s disease. Clin Rheumatol 2010;29:209-10
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, et al. Resistant Behcet disease responsive to anakinra. Ann Intern Med 2008;149:284-6
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behcet uveitis: why not? Clin Exp Rheumatol 2013;31:152-3
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet’s disease: a case series. Dermatology 2014;228:211-14
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behcet’s disease. Clin Exp Rheumatol 2012;30:S115
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 2012;71(9):1589-91
   PubMed Web of Science ®Google Scholar
• Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 2012;71:563-6
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13:246-52
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 2014;32:S75-9
   PubMed Web of Science ®Google Scholar
• Addimanda O, Pipitone N, Pazzola G, Salvarani C. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum 2015;44:472-5
   PubMed Web of Science ®Google Scholar
• Caso F, Iaccarino L, Bettio S, et al. Refractory pemphigus foliaceus and Behcet’s disease successfully treated with tocilizumab. Immunol Res 2013;56:390-7
   PubMed Web of Science ®Google Scholar
• Redondo-Pachon MD, Enriquez R, Sirvent AE, et al. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet’s disease. Ren Fail 2013;35:547-50
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003;42:1539-44
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul Immunol Inflamm 2007;15:63-70
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behcet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 2013;72:626-7
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for the treamtent of Behcet`s syndrome: A phase II randomized, placebo-controlled, double-blind study. Ann Rheum Dis 2013;72(Suppl3):486
   Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome--a phase 2, placebo-controlled study. N Engl J Med 2015;372:1510-18
   PubMed Web of Science ®Google Scholar
• Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet 2010;42:698-702
   PubMed Web of Science ®Google Scholar
• Cavus F, Ulusoy C, Orcen A, et al. Increased IL-23 receptor, TNF-alpha and IL-6 expression in individuals with the IL23R-IL12RB2 locus polymorphism. Immunol Lett 2014;160:96-8
   PubMed Web of Science ®Google Scholar